A Framework For Selecting Reliable Clinical Endpoints From Real-World DHT Data

Dr. Andy Liu, Biostatistician at ActiGraph, presents a case study determining which digital measure of physical activity would be a well-defined and reliable clinical endpoint in a trial including patients with diabetes. Using real-world digital data collected in the NHANES population study, he discusses the advantages and challenges of using continuous data from sensor-based wearable digital health technologies to develop clinical trial endpoints, and using this specific case study as an example, shares a framework for evaluating digital measures to help study teams select a reliable clinical endpoint.